Eupraxia Pharmaceuticals Inc. $EPRX Shares Sold by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. reduced its position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) by 90.9% during the second quarter, HoldingsChannel reports. The firm owned 9,600 shares of the company’s stock after selling 95,386 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Eupraxia Pharmaceuticals were worth $56,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of EPRX. Scotia Capital Inc. raised its position in shares of Eupraxia Pharmaceuticals by 11.6% in the 1st quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company’s stock valued at $5,072,000 after purchasing an additional 160,960 shares in the last quarter. Royal Bank of Canada lifted its position in shares of Eupraxia Pharmaceuticals by 21.1% in the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after buying an additional 59,683 shares during the last quarter. Finally, Ingalls & Snyder LLC bought a new position in Eupraxia Pharmaceuticals in the second quarter worth about $214,000.

Eupraxia Pharmaceuticals Trading Down 1.1%

EPRX stock opened at $6.13 on Wednesday. Eupraxia Pharmaceuticals Inc. has a 52 week low of $2.68 and a 52 week high of $7.19. The company has a market capitalization of $220.43 million, a price-to-earnings ratio of -7.05 and a beta of 1.47. The firm’s 50-day moving average is $5.92 and its two-hundred day moving average is $5.24.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. On average, equities research analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Eupraxia Pharmaceuticals in a report on Wednesday, August 20th. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Leede Financial upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.